1. Home
  2. PINE vs LUNG Comparison

PINE vs LUNG Comparison

Compare PINE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpine Income Property Trust Inc.

PINE

Alpine Income Property Trust Inc.

HOLD

Current Price

$19.19

Market Cap

277.5M

Sector

Real Estate

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.57

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PINE
LUNG
Founded
2019
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Industrial Specialties
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
277.5M
57.9M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
PINE
LUNG
Price
$19.19
$1.57
Analyst Decision
Strong Buy
Buy
Analyst Count
5
7
Target Price
$20.10
$5.38
AVG Volume (30 Days)
168.5K
520.2K
Earning Date
04-23-2026
04-29-2026
Dividend Yield
6.29%
N/A
EPS Growth
N/A
7.64
EPS
0.06
N/A
Revenue
$60,532,000.00
$90,497,000.00
Revenue This Year
$18.63
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$317.50
N/A
Revenue Growth
15.90
8.01
52 Week Low
$13.10
$1.13
52 Week High
$20.80
$3.88

Technical Indicators

Market Signals
Indicator
PINE
LUNG
Relative Strength Index (RSI) 51.02 66.44
Support Level $18.72 $1.51
Resistance Level $19.98 $1.64
Average True Range (ATR) 0.39 0.09
MACD -0.02 0.04
Stochastic Oscillator 41.77 82.34

Price Performance

Historical Comparison
PINE
LUNG

About PINE Alpine Income Property Trust Inc.

Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: